|
| Friday, November 1, 2024 |
|
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). more info >> |
|
| Thursday, October 31, 2024 |
|
|
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Clinical Trials for Alzheimer's Disease Conference (CTAD), held in Madrid, Spain, and virtually. more info >> |
|
|
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) |
| Eisai Co. Ltd announced today that the latest findings on anti-MTBR (microtubule binding region) tau antibody E2814 were presented at the 17th annual Clinical Trials on Alzheimer's Disease (CTAD) conference, held in Madrid, Spain, and virtually. more info >> |
|
| Thursday, October 17, 2024 |
|
|
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association |
| Shimadzu Corporation, Eisai Co., Ltd., Oita University, and Usuki City Medical Association have demonstrated the utility of blood biomarkers in predicting the accumulation of amyloid beta (Abeta)(1) in the brain, a noted cause of Alzheimer's disease(2), in a cohort study conducted in Usuki City, Oita from November 2022. more info >> |
|
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to register the humanized anti-solubleaggregated amyloid-beta (Abeta) monoclonal antibody lecanemab for the treatment of patients with mild cognitive impairment (MCI)due to Alzheimer's disease (AD) and mild AD dementia. more info >> |
|
| Wednesday, October 16, 2024 |
|
|
Amyotrophic Lateral Sclerosis Treatment "Rozebalamin(R) for Injection 25 mg" Receives The Good Design Award 2024 for Light- Proof Vial Packaging |
| Eisai Co., Ltd. announced today that amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin(R) for Injection 25 mg" (mecobalamin) has received the Good Design Award 2024 (by the Japan Institute of Design Promotion) for its light-proof vial packaging. more info >> |
|
| Tuesday, October 8, 2024 |
|
|
エーザイ、痛風・高尿酸血症治療剤「URECE(R) Tablets」（一般名：ドチヌラド）についてタイで承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、痛風・高尿酸血症治療剤「URECE(R) Tablets」（一般名：ドチヌラド）について、タイにおいて「痛風、高尿酸血症」の適応で承認を取得したことをお知らせします。 more info >> |
|
|
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia |
| Eisai Co., Ltd. announced today that it has received approval for "URECE Tablets" (dotinurad) in Thailand as a treatment for gout and hyperuricemia. more info >> |
|
| Wednesday, October 2, 2024 |
|
|
エーザイ、サウジアラビアの医薬品販売子会社が事業活動を開始 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、サウジアラビア王国（以下、サウジアラビア）のリヤドに設立した医薬品販売会社「Eisai Pharmaceuticals Single Person Limited Liability Company」（以下、エーザイ・サウジアラビア）が本格稼働し、事業活動を開始したことをお知らせします。 more info >> |
|
|
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia |
| Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Pharmaceuticals Single Person Limited Liability Company (Eisai Saudi Arabia), a pharmaceutical sales subsidiary recently established in Riyadh in the Kingdom of Saudi Arabia (Saudi Arabia). more info >> |
|
|
|
|
